Product Description
Memo Therapeuitcs AG’s (“MTx”) lead program, AntiBKV, is a highly effective and safe neutralizing antibody to treat BK virus infection in kidney transplant recipients. MTx’ pipeline consists of additional therapeutic antibodies focusing on infectious diseases, such as cytomegalovirus (“CMV”), undisclosed immuno-oncology targets as well as a partnership with Ono Pharmaceutical. (Sourced from: https://memo-therapeutics.com/pipeline.html)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Antibody
Route of Administration: N/A
FDA Designation: Fast Track - Renal Transplant *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Memo Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Kidney Transplant
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| SAFE KIDNEY II | P3 |
Active, not recruiting |
Kidney Transplant |
2025-03-19 |
14% |
2025-03-14 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/07/2024 |
News Article |
Memo Therapeutics increases Series C financing to CHF 45 million |
|
02/05/2024 |
News Article |
Memo Therapeutics AG Strengthens Management Team |
|
11/16/2023 |
News Article |
Memo Therapeutics AG Appoints Erik van den Berg as Chief Executive Officer |
|
11/02/2023 |
News Article |
Memo Therapeutics AG Raises CHF 25 Million Series C Financing to Complete Phase II Clinical Development of AntiBKV for BKV Infection in Renal Transplant Patients |
|
09/21/2023 |
PubMed |
Pretransplant BKV-IgG serostatus and BKV-specific ELISPOT assays to predict BKV infection after kidney transplantation. |
|
04/01/2023 |
PubMed |
BK virus genotypes and humoral response in kidney transplant recipients with BKV associated nephropathy. |
|
01/01/2022 |
PubMed |
Current Status, Prevention and Treatment of BK Virus Nephropathy. |